A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100(Clemizole HCl) as Adjunctive Therapy in Patients with Dravet Syndrome (ARGUS trial) A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100(ClemizoleHCl) ...
A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100(Clemizole HCl) as Adjunctive Therapy in Patients with Dravet Syndrome (ARGUS trial) A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100(ClemizoleHCl) ...
Dravet Syndrome;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: EPX-100(ClemizoleHydrochloride) Product Code: EPX-100 INN or Proposed INN: CLEMIZOLE HYDROCHLORIDE Product Name: EPX-100(ClemizoleHydrochloride) Product Code: EPX-100 INN or Proposed INN: CLEMIZOLE H ...
EPX-100(ClemizoleHydrochloride) as Add-on Therapy to Control Convulsive Seizures in Patients With Dravet Syndrome EPX-100(ClemizoleHydrochloride)as Add-on Therapy to Control Convulsive Seizures in Patients With D ...
A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100(ClemizoleHydrochloride) as Adjunctive Therapy in Children and Adult Participants With Dravet Syndrome (ARGUS Trial) A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100(ClemizoleHydr ...
Study of Safety and Pharmacokinetics of Oral Doses of EPX-100 in Healthy Subjects.
A Phase I, Placebo-Controlled, Double-Blind, 2-Period Study to Assess Safety and Pharmacokinetics of Escalating Single and Multiple Oral Doses of EPX-100 in Fasting Healthy Subjects and Following a High-Fat Meal A Phase I, Placebo-Controlled, Double-Blind, 2-Period Study to Assess Safety and Pharmacokinetics of ...